neladenoson bialanate

a prodrug of neladenoson, a partial adenosine A1 receptor agonist; structure in first source

Also Known As:

2-(4-(2-(((2-(4-chlorophenyl)-1,3-thiazol-4-yl)methyl)sulfanyl)-3,5-dicyano-6-(pyrrolidin-l-yl)pyridin-4-yl)phenoxy)ethyl L-alanyl-L-alaninate

Networked: 6 relevant articles (1 outcomes, 4 trials/studies)

1.	Bax, Jeroen J: 3 articles (11/2019 - 01/2017)
2.	Butler, Javed: 3 articles (11/2019 - 01/2017)
3.	Voors, Adriaan A: 3 articles (11/2019 - 11/2018)
4.	Hernandez, Adrian F: 2 articles (11/2019 - 11/2018)
5.	Senni, Michele: 2 articles (11/2019 - 01/2017)
6.	van der Laan, Michael: 2 articles (11/2019 - 11/2018)
7.	Kitzman, Dalane W: 2 articles (01/2019 - 11/2018)
8.	McMurray, John J V: 2 articles (01/2019 - 11/2018)
9.	Shah, Sanjiv J: 2 articles (01/2019 - 11/2018)
10.	Solomon, Scott D: 2 articles (01/2019 - 11/2018)

1.	Heart Failure 01/01/2017 - "Neladenoson bialanate hydrochloride is currently being evaluated in clinical trials for the treatment of heart failure." 11/01/2019 - "We aimed to assess the dose-response effect of neladenoson bialanate on cardiac structure and function, clinical outcome, and safety in patients with heart failure (HF) with reduced ejection fraction (HFrEF). " 01/01/2019 - "Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial." 11/01/2019 - "Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial." 01/01/2019 - "Based on preclinical studies, neladenoson bialanate, a first-in-class partial adenosine A1 receptor agonist, has the potential to improve several heart failure-related cardiac and noncardiac abnormalities but has not been evaluated to treat HFpEF. "
2.	Heart Diseases (Heart Disease) 01/01/2017 - "Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases."